These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24310736)

  • 1. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
    Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
    Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
    Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
    Bavelloni A; Focaccia E; Piazzi M; Orsini A; Ramazzotti G; Cocco L; Blalock W; Faenza I
    J Cell Physiol; 2019 Jul; 234(7):10907-10917. PubMed ID: 30536897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
    Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
    Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
    Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
    Shiri Heris R; Safaroghli-Azar A; Yousefi AM; Hamidpour M; Bashash D
    Cell Biol Int; 2020 May; 44(5):1212-1223. PubMed ID: 32068318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
    Zhao P; Hall J; Durston M; Voydanoff A; VanSickle E; Kelly S; Nagulapally AB; Bond J; Saulnier Sholler G
    PLoS One; 2017; 12(6):e0179948. PubMed ID: 28662162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
    Brachmann SM; Kleylein-Sohn J; Gaulis S; Kauffmann A; Blommers MJ; Kazic-Legueux M; Laborde L; Hattenberger M; Stauffer F; Vaxelaire J; Romanet V; Henry C; Murakami M; Guthy DA; Sterker D; Bergling S; Wilson C; Brümmendorf T; Fritsch C; Garcia-Echeverria C; Sellers WR; Hofmann F; Maira SM
    Mol Cancer Ther; 2012 Aug; 11(8):1747-57. PubMed ID: 22653967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
    Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
    PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
    Amrein L; Shawi M; Grenier J; Aloyz R; Panasci L
    Int J Cancer; 2013 Jul; 133(1):247-52. PubMed ID: 23238639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.